Cellzome AG to Study Epigenetic Factors with Neusentis

Published: May 10, 2011

Heidelberg, Germany – 10 May 2011 – Cellzome announced today a joint project with Pfizer’s Pain & Sensory Disorders and Regenerative Medicine unit ‘Neusentis’, to characterize epigenetic factors involved in stem cell differentiation using Cellzome’s EpisphereTM technology.

The aim of the project is to shed light on the epigenetic mechanisms involved in the regulation of stem cell differentiation. Pfizer will provide its know-how in stem cell handling and regenerative medicine, while Cellzome will apply its world-leading chemoproteomics platform to chart the changes of epigenetic factors during stem cell differentiation.

Tim Edwards, CEO of Cellzome said: “This is a very exciting collaboration in an emerging area of science. Cellzome can monitor epigenetic factors in their natural complexes directly throughout stem cell differentiation. We look forward to working with Pfizer to gain fundamental insights into epigenetic regulation which may be instrumental for any therapeutic applications in regenerative medicine.”

For more information please contact:

Cellzome:

Tim Edwards

Chief Executive Officer

Tel: +49 (0) 6221-137 57-100

press@cellzome.com

Media contact:

Nicole Yost, Jayne Crook

College Hill

Tel: +44 (0)20 7866 7862

cellzome@collegehill.com

Back to news